VERY STRONG REVENUES AND EARNINGS INCREASE IN 2023

Donaueschingen, 05/03/2024: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its revenues by 15.5% and EBT by 21% in the fiscal year 2023. As a result, the continually positive development of revenues and earnings of the last two decades could be continued.

In 2023 hat sich der Umsatz von TEUR 209.128 auf TEUR 241.459 (+15,5 %) erhöht. Im Segment „NEXUS / DE“ stieg der unkonsolidierte Umsatz von TEUR 69.915 auf TEUR 80.348 (+14,9 %), bei „NEXUS / DIS“ von TEUR 51.166 auf TEUR 59.687 (+16,7 %) und bei „NEXUS / ROE“ auf TEUR 113.888 (Vj: TEUR 97.590) (+16,7 %). Der Anteil des internationalen Geschäftes am Gesamtumsatz betrug 45,3 % (Vj: 46,4 %) und erreichte TEUR 109.261 nach TEUR 96.978 im Vorjahr.

In 2023, revenues improved from KEUR 209,128 to KEUR 241,459 (+15.5%). The “NEXUS / DE” segment increased the unconsolidated revenues from KEUR 69,915 to KEUR 80,348 (+14.9%), “NEXUS / DIS” increased from KEUR 51,166 to KEUR 59,687 (+16.7%) and “NEXUS / ROE” increased to KEUR 113,888 (previous year: KEUR 97,590) (+16.7%). The international share of total business volume was 45.3% (2022: 46.4%) and amounted to KEUR 109,261 compared to KEUR 96,978 (2022).

The consolidated earnings before taxes (EBT) rose very sharply by 21% to KEUR 32,994 (2022: KEUR 27,260). The EBIT rose by 14.7% to KEUR 31,873 (2022: KEUR 27,788), the EBITA rose by 17.6% from KEUR 32,557 (2022) to KEUR 38,276. EBITDA increased by 13.8% to KEUR 50,389 (2022: KEUR 44,292), the consolidated surplus increased by 20.4% to KEUR 23,792 (2022: KEUR 19,769). Earnings per share (diluted/undiluted) increased from EUR 1.21 (2022) to EUR 1.39 and thus by 14.9% in line with revenues.

Operating cash flow decreased by -10.2% to KEUR 30,407 (2022: KEUR 33,875) and remains at a very high level. At the end of 2023, the company had cash resources at its disposal in the amount of KEUR 97,434 (31/12/2022: KEUR 110,019). The slight reduction is mainly due to the investment in acquired companies.

Nexus AG had equity capital amounting to KEUR 258,582 as of 31/12/2023 (31/12/2022: KEUR 238,946). Consequently, the equity capital rate is 62.8% (31/12/2022: 69.4%). This demonstrates that Nexus AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.

At the annual general meeting on 15/05/2024, the Supervisory Board and the Executive Board will propose to pay a dividend of EUR 0.22 per share.

You might also be interested in

    • NEXUS-Gruppe

    VERY STRONG REVENUES AND EARNINGS INCREASE IN 2022

    Donaueschingen, 07/03/2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its revenues by 11.1% and EBIT by 15.2% in the fiscal year 2022. As a result, the continually positive development of revenues and earnings of the last two decades could be continued.

    • NEXUS-Gruppe

    Strong sales and earnings increase in the first half-year 2023

    Donaueschingen, 15 August 2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by approx. 12% and EBT by 23% in the first six months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.

    • NEXUS-Gruppe

    VERY STRONG SALES AND EARNINGS INCREASE IN THE FIRST QUARTER 2023

    Donaueschingen, 16/05/2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 11% and EBIT by approx. 28% in the first three months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.

    • NEXUS-Gruppe

    Very strong sales and earnings increase in the third quarter 2023

    Donaueschingen, 07/11/2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 14% and EBT by approx. 33% in the first nine months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.

Do you need help? We are happy to advise you.
Contact Mail
X
Lightbulb
What are you looking for? Fachbereiche, Experten, Behandlungsschwerpunkte und Standorte
Nicht das gewünschte Ergebnis? Nutzen Sie die globale Suche. Zur Suche